Risk of Cardiomyopathy in Breast Cancer: How Can We Attenuate the Risk of Heart Failure from Anthracyclines and Anti-HER2 Therapies?
Kimmick G, Dent S, Klem I
Curr Treat Options Cardiovasc Med. 2019 May 31;21(6):30
CARDIONCOLOGY.ORG ABSTRACT:
Cardiotoxicity from anthracyclines and anti-HER2 therapies has to be kept in mind, particulary in the adjuvant setting.
Data from recent randomized clinical trials suggest that the use of angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), and beta blockers may prevent subclinical cardiotoxicity, and may even prevent subsequent cardiomyopathy.
© All rights reserved
Image source: https://www.upi.com/Health_News/2016/08/15/Cancer-passes-heart-disease-as-top-killer-in-12-European-countries/3291471261826/